Chiesi Farmaceutici
Highly Engaged Employees
Manufacturing · Italy · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
Via Palermo 26 a 1, Parma, Emilia-Romagn...Phone Number
+39 3395897483Website
www.chiesi.comRevenue
$3.3 BillionIndustry
About Chiesi Farmaceutici
Chiesi Farmaceutici Org Chart
Is Chiesi Farmaceutici your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Chiesi Farmaceutici launches new products
Earning: See what the market has to say on Chiesi Farmaceutici recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Chiesi Farmaceutici is spiking on competitors!
Funding: Get notified immidiatlly once Chiesi Farmaceutici has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Chiesi Farmaceutici has recently received funding, and reach out quickly before it becomes old news!
Click to see if Chiesi Farmaceutici had a recent Job posting/layoffs
Chiesi Farmaceutici, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Chiesi Farmaceutici
Recommended Actions
Find VP level buyers at Chiesi Farmaceutici
Find more new buyers
Company Profile Activity
Activity Insights
Chiesi Farmaceutici is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Chiesi Farmaceutici is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Chiesi Farmaceutici.
Chiesi Farmaceutici Tech Stack
A closer look at the technologies used by Chiesi Farmaceutici
Most Recent Scoops
Chiesi Farmaceutici News & Media
Chiesi Global Rare Diseases Demonstrates Its Ongoing Commitment to the Rare Disease Community at the Society of Inborn Errors of Metabolism (SSIEM) 2026 Annual Symposium
-- Chiesi’s abstract presentations highlight clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- Rooted in patient voice and scientific rigor, this research reflects Chiesi’s long-standing role in advancing science for the lysosomal storage disorders community --NSG Bio Accelerates Breakthrough Biotech Innovation in Singapore
New initiative under NSG Bio Tomorrow will support promising startups developing next-generation approaches in respiratory and neonatal care SINGAPORE, July 22, 2026 /PRNewswire/ -- The NSG Bio Tomorrow initiative aims at supporting emerging life sciences startups working on complex challenges in respiratory and neonatal care. Launched through the support of Chiesi Group, The Impulse initiative will provide a selected startup with one year of NSG Bio membership and access to a dedicated laboratoChiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria
ABO-101 is an investigational gene editing therapy designed to address the underlying disease biology of PH1 by reducing hepatic oxalate productionChiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria
ABO-101 is an investigational gene editing therapy designed to address the underlying disease biology of PH1 by reducing hepatic oxalate production
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Chiesi Farmaceutici
Chiesi Farmaceutici SpA is a pharmaceutical company providing research, development, production, and marketing of therapeutic solutions for respiratory, primary, neonatology, and rare disease care. Chiesi was founded in 1935 and is headquartered in Parma, Italy.... Read More